This is the authors' abstract. We don't add key points for this paper.
Mononuclear copper(II) and zinc(II) complexes of composition [Cu(2-AEP)(BA) 2 ] 1, [Cu(2-AEP)(TPAA) 2 ] 2 , [Zn(2-AEP)(Cl) 2 ] 3 , [Zn(2-AEP) 2 ](ClO 4 ) 2 4 , and [Zn(2-AEP)(TPAA) 2 ] 5 , were synthesized by using, 2-aminoethylpyridine (2-AEP) as ligand, benzoic acid (BA) and triphenylaceticacid (TPAA) as ancillary ligands. Complexes 1-5 were characterized using elemental study, UV-Vis, FT-IR, ESI-MS, and ESR spectroscopy (incase of Cu). Single crystal XRD of complexes revealed 1 in octahedral, 2 & 5 in square pyramidal and 3 & 4 in tetrahedral geometry. The interactions towards DNA with complexes 1-5 were studied by spectral titration, electrochemical techniques, and CD measurements. These complexes were interacted strongly via groove binding with CT-DNA with binding efficacy in the range k b = 0.45-4.69 × 10 4 M -1 . Among the complexes, zinc(II) complex 4 showed higher binding affinity than remaining complexes ( 1 - 3 , 5 ). The binding affinity order is 4 > 5 > 3 > 1 > 2 . In addition, copper(II) complexes ( 1 and 2 ) showed catecholase like activity with reaction rate, k = 2.68 × 10 -3 M s -1 and 2.63 × 10 -3 M s -1 respectively.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sureshbabu et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: